teensexonline.com

Incyte’s Oral JAK Inhibitor Shows Durable Efficacy, Safety At One Year In Skin Disorder – Incyte (NASDAQ:INCY)

Date:

  • Incyte Corporation INCY announced new 52-week results from a Phase 2 study evaluating the efficacy and safety of povorcitinib (formerly INCB54707), an oral JAK1 inhibitor, in adult patients with hidradenitis suppurativa (HS). 
  • The study previously met its primary endpoint, demonstrating that at Week 16 – patients receiving povorcitinib once daily (QD) had significantly greater decreases from baseline in Abscess and Inflammatory Nodule (AN) count versus placebo.
  • Related: Incyte Q4 Earnings Beat Street View, But Guidance Is Conservative Says Analyst.
  • Results at Week 52, which include the 36-week open-label extension period during which all patients received povorcitinib 75 mg QD, show that average efficacy was sustained for all treatment arms following the switch to povorcitinib 75 mg QD.
  • Povorcitinib also demonstrated durable efficacy at Week 52 in high-threshold outcomes, as evidenced by 22-29% of patients achieving HS Clinical Response 100 (HiSCR100).
  • Price Action: INCY shares are down 0.98% at $80.44 on the last check Friday.

Share post:

Subscribe

Popular

More like this
Related